Ildong Holdings Co., Ltd. (KRX:000230)
11,760
+2,710 (29.94%)
At close: Nov 5, 2025
Ildong Holdings Revenue
Ildong Holdings had revenue of 148.84B KRW in the quarter ending June 30, 2025, a decrease of -5.64%. This brings the company's revenue in the last twelve months to 635.42B, up 0.30% year-over-year. In the year 2024, Ildong Holdings had annual revenue of 657.57B with 2.99% growth.
Revenue (ttm)
635.42B
Revenue Growth
+0.30%
P/S Ratio
0.16
Revenue / Employee
8.83B
Employees
72
Market Cap
102.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 657.57B | 19.12B | 2.99% |
| Dec 31, 2023 | 638.45B | -37.09B | -5.49% |
| Dec 31, 2022 | 675.54B | 83.17B | 14.04% |
| Dec 31, 2021 | 592.37B | -4.09B | -0.69% |
| Dec 31, 2020 | 596.47B | 304.25B | 104.12% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |